A5111833147- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Ovarian cancer diagnosis and treatment
- Cancer Genomics and Diagnostics
- Renal cell carcinoma treatment
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Central Venous Catheters and Hemodialysis
- Health and Lifestyle Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer, Lipids, and Metabolism
- Neuropeptides and Animal Physiology
- Venous Thromboembolism Diagnosis and Management
- Schizophrenia research and treatment
- Estrogen and related hormone effects
- Pain Mechanisms and Treatments
- Neuroendocrine Tumor Research Advances
- Cancer Immunotherapy and Biomarkers
- Chemotherapy-related skin toxicity
- HER2/EGFR in Cancer Research
- Stress and Burnout Research
- Neutropenia and Cancer Infections
Central University Hospital of Asturias
2011-2025
Hospital Universitario Puerta de Hierro Majadahonda
2021
Instituto de Investigación Sanitaria del Principado de Asturias
2002-2011
Hospital de León
2006
Universidad de Oviedo
2002-2003
Article AbstractBackground: This naturalistic cross-sectional survey of patients with severe mental illnesses explores the association between important variables and obesity, extreme diabetes mellitus type 2, hypertension, hyperlipidemia in clinical environment. Method: Weight height were obtained from 560 (including DSM-IV schizophrenia, schizoaffective disorder, bipolar major depressive disorder) at central Kentucky inpatient outpatient facilities to estimate their body mass index (BMI)....
Background Based on the excellent results of clinical trials with ALK-inhibitors, importance accurately identifying ALK positive lung cancer has never been greater. However, there are increasing number recent publications addressing discordances between FISH and IHC. The controversy is further fuelled by different regulatory approvals. This situation prompted us to investigate two IHC antibodies (using a novel ultrasensitive detection-amplification kit) an automated scanning system...
Abstract The May Measurement Month (MMM) campaign was carried out in the Philippines 2022 with aim of raising awareness raised blood pressure (BP). Here, we report on findings campaign. Adults aged ≥ 18 years were recruited opportunistically at hospitals, doctor‘s clinics, health centres under local government units, private companies (pharmaceutical and corporates), drug stores, others. Three seated BP readings taken for each participant, along completion a questionnaire demographics,...
Lorlatinib, a third-generation tyrosine kinase inhibitor (TKI), targets both ALK and ROS1 rearrangements in non-small cell lung cancer (NSCLC). It is approved for ALK-positive patients after progression on prior TKIs but lacks FDA or EMA approval ROS1-positive NSCLC. This study evaluates lorlatinib's efficacy safety ALK- through compassionate use program Spain. We analyzed treated from November 2016 to February 2019 March 2021. Eligible had Stage IV NSCLC with confirmed TKI therapy. For...
Treatment options for patients with high-grade pancreatic neuroendocrine tumors (pNET) are limited, especially those progressive disease and who experience treatment failure. Everolimus, an oral inhibitor of mammalian target rapamycin (mTOR), has been approved the low- or intermediate-grade advanced pNET. In randomized phase III RADIANT-3 study in pNET, everolimus significantly increased progression-free survival (PFS) decreased relative risk progression by 65% over placebo. This case report...
Introduction Pegylated liposomal doxorubicin (PLD) is currently the reference treatment for platinum-resistant ovarian cancer. The combination of PLD and gemcitabine administration at a fixed dose rate infusion (FDRI) seem to have additive activity in this disease setting. We launched phase Ib study with FDRI followed by recurrent cancer platinum-free interval less than 1 year, parallel pharmacokinetic pharmacogenetic studies. Methods starting was 1500 mg/m 2 , 10 per minute, every weeks...
Mutations in tyrosine kinase domain of epidermal growth factor receptor (EGFR) are observed approximately 15% non-small cell lung cancer adenocarcinoma. Exon 19 deletions or exon 21 L858R mutations predominant frequency and show high sensitivity to EGFR inhibitors (TKIs). 18 extremely rare the delE709_T710insD mutation accounts for only 0.16% when occurring as a sole mutation. This specific seems respond certain TKIs such afatinib. However, given rarity this mutation, determining most...
According to premarketing studies, at least 1% of ziprasidone‐treated patients exhibited hypertension; however, this figure is not necessarily attributable the drug. A PubMed/MEDLINE search yielded no articles describing hypertension as a possible adverse event associated with oral ziprasidone therapy. We describe 53‐year‐old African‐American woman and schizophrenia whose blood pressure increased during She experienced similar increases therapy four other atypical antipsychotics. Her mean...
665 Background: It is widely known the causal relationship establised between tobacco use and development of renal cancer known. Nevertheless, impact smoking on efficacy safety anti-angiogenic drugs unclear. Sunitinib a tyrosine kinase inhibitor with proven metastatic cell carcinoma (mRCC). Methods: A retrospective analysis was carried out including 194 mRCC patients (pts) who received in single Institution (Hospital Universitario Central de Asturias) high incidence this disease. The aim...
17052 Background: Previous comparative studies have shown similar efficacy and less toxicity with either the Gemcitabine(G)/Vinorelbine(V) or Gemcitabine/Docetaxel(D) combination respect to platinum-based chemotherapies in patients advanced NSCLC. This trial was designed test safety of both GV GD non-selected Methods: Patients (n = 39) ≤75 years age, KPS ≥ 60% adequate haematological, renal hepatic function were randomly assigned to: G 1250 mg/m 2 i.v. d1 d8 plus V 25 D 35 every 3 weeks....
e12609 Background: There are numerous surveys on prevalence of cancer-related pain. However, given the limitation small patient samples, results not strong enough to determine pain in uncommon tumors. The primary objective ATLAS study was therefore collect data needed assess all different tumor entities. A second aim satisfaction with analgesic treatment. Methods: Non-interventional, post-authorization, observational study, an initial screening period for up one month, performed by 35...